Kalvista Pharmaceuticals Inc (KALV) - News Archive

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), recently provided an operational update and announced its financial results for the fiscal year ending April 30, 2024. According to...

KalVista Pharmaceuticals: Recent Developments in Inducement Grants, New Drug Applications, and Conference Presentations KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cambridge,...

Cambridge, Mass. & Salisbury, England - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a leading pharmaceutical company, has recently announced the initiation of the KONFIDENT-KID clinical trial. The trial aims to evalu...

KalVista Pharmaceuticals, a leading biopharmaceutical company, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sebetralstat. This oral plasma kallikrein inhibitor s...

KalVista Pharmaceuticals Showcases Breakthrough Data at Major Medical Conferences: A Comprehensive OverviewKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a trailblazer in the pharmaceutical industry, recently unveiled g...

KalVista Pharmaceuticals, a leading clinical stage pharmaceutical company, presented compelling real-world data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, held in Valencia, Spain....

KalVista Pharmaceuticals, a clinical-stage pharmaceutical company, recently announced the publication of late-breaking data from the pivotal phase 3 KONFIDENT trial and open-label KONFIDENT-S extension trial in The New...

KalVista Pharmaceuticals Announces Ten s Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ:...

The field of genetic medicine has witnessed remarkable advancements, with innovative pharmaceutical companies pushing boundaries to find effective solutions for genetic diseases. One such company, KalVista Pharmaceutica...

KalVista Pharmaceuticals, a leading biopharmaceutical company specializing in the development of novel therapies, has recently unveiled its strategic plans for fiscal year 2025. With its comprehensive approach and groun...

In recent updates, KalVista Pharmaceuticals, a clinical stage pharmaceutical company, has presented new findings and data at various conferences, emphasizing the impact of treatment delays on the clinical outcomes of in...

KalVista Pharmaceuticals, a renowned clinical stage pharmaceutical company specializing in the development and commercialization of oral, small molecule protease inhibitors, proudly announces multiple achievements in th...

KalVista Pharmaceuticals Advances in Clinical Trials and Financial Performance, Pursuing Promising Therapies for Hereditary AngioedemaCAMBRIDGE, Mass. & SALISBURY, England- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV),...

aims to provide an and comprehensive analysis of recent developments in the pharmaceutical industry. In this article, we will outline the key facts from the articles KalVista Pharmaceuticals to Present HAE Attack Journe...

KalVista Pharmaceuticals, a clinical stage pharmaceutical company specializing in oral, small molecule protease inhibitors, has recently announced the appointment of Benjamin L. Palleiko as its new Chief Executive Offic...

KalVista Pharmaceuticals Announces Inducement Grants to Newly-Hired Employees: How It Impacted the Shareholders and Boosted Share Price by 16.38% in Q1 2024 CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceutica...

KalVista Pharmaceuticals, a leading clinical-stage pharmaceutical company, recently unveiled additional data from its phase 3 KONFIDENT trial involving sebetralstat at the 2024 American Academy of Allergy, Asthma & Immu...

In a recent development, KalVista Pharmaceuticals, a renowned clinical stage pharmaceutical company, has been granted the UK Innovation Passport for its novel investigational drug, sebetralstat. This oral plasma kallikr...

KalVista Pharmaceuticals, a clinical stage pharmaceutical company, has recently announced positive results from the phase 3 KONFIDENT clinical trial. The trial demonstrates the efficacy of sebetralstat as the first oral...

KalVista Pharmaceuticals, Inc. recently made an announcement regarding the granting of inducement options to four newly-hired employees, with a total of 42,000 shares of the company s common stock. This news comes in ac...